Research on Embryonic Stem Cell-Derived Retinal Cells for Vision Loss

Overview of Age-Related Macular Degeneration

A study conducted by a research group in California explored the potential of embryonic stem-cell-derived retinal cells coupled with a scaffold implant to address vision loss. Age-related macular degeneration (AMD) impacts 10-20% of the adult population in developed countries. This progressive condition currently lacks treatment options for individuals suffering from advanced stages.

The Role of Retinal Pigment Epithelium in Vision

Vision loss in AMD is primarily linked to the significant deterioration of the retinal pigment epithelium (RPE), a layer outside the retina that nourishes ocular cells. Human embryonic stem cells have been utilized to produce lab-grown RPE, which could serve as a therapeutic resource for retinal degeneration in AMD patients.

Injecting RPE from Embryonic Stem Cells

Challenges in RPE Cell Localization

Injecting RPE derived from embryonic stem cells into the retina has shown some promise in partially restoring RPE loss and slightly enhancing vision. Despite the safety and efficacy of this procedure, a major challenge remains: the RPE cells do not migrate to the areas of RPE decline but instead settle outside these regions. This misplacement indicates a lack of organizational signals necessary for proper integration within the eye.

The Need for a Supporting Framework

Replacing RPE alone is insufficient for restoring the structural and functional integrity of the affected areas. Therefore, it is crucial to develop a supporting framework to be transplanted alongside the embryonic stem cell-derived RPE to promote proper cellular organization.

Implementing a Synthetic Scaffold for RPE Restoration

Research Findings on Synthetic Scaffolds

The California research group published their findings in *Science Translational Medicine*, detailing the design and application of a synthetic scaffold intended to facilitate the attachment and organization of embryonic stem cell-derived RPE at sites of RPE loss.

Previous Studies and Human Trials

The same team had previously demonstrated the scaffold’s safety and functionality in animal models, including mice and pigs. In their recent study, they included five human subjects, four of whom successfully received the scaffold implant. All participants were diagnosed with advanced AMD and exhibited severe RPE loss. Researchers monitored the subjects for 120 to 365 days post-implantation.

Results and Implications of the Study

Successful Integration and Vision Improvement

Post-operative imaging revealed successful implantation of the RPE, which began to integrate with surrounding ocular tissues. Notably, no adverse effects or safety concerns were reported among the participants. One subject demonstrated significant improvement in vision, which correlated with the enhanced structural support provided by the scaffold and RPE. Additionally, all subjects exhibited anatomical changes in the eye and a gradual reappearance of RPE over the implant. Importantly, none showed further vision loss.

Potential for Clinical Application

These preliminary findings suggest that bioengineered implants could offer a viable clinical solution for advanced AMD. The subjects in this study represented the most severe cases, and their positive outcomes provide hope for future applications. Expanding the sample size will be essential to determine the statistical and clinical significance of these results. The combination of embryonic stem cells for RPE generation and innovative scaffolds presents exciting possibilities for maintaining the structural integrity of implanted tissues.

Conclusion

This research highlights the potential of using embryonic stem cells and synthetic scaffolds in treating advanced AMD, paving the way for future advancements in therapies aimed at improving vision in affected individuals.

References

Kashani, A.H., Lebkowski, J.S., Rahhal, F.M., Avery, R.L., Salehi-Had, H., Dang, W., Lin, C., Mitra, D., Zhu, D., Thomas, B.B., Hikita, S.T., Pennington, B.O., Johnson, L.V., Clegg, D.O., Hinton, D.R., Humayun, M.S. (2018) A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. *Science Translational Medicine*, 10; 435. DOI: 10.1126/scitranslmed.aao4097